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Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide
and 5-Year Mortality Risk in Stable Coronary Artery Disease: The
Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient
Cohort
Vichai Senthong, MD; Zeneng Wang, PhD; Xinmin S. Li, PhD; Yiying Fan, PhD; Yuping Wu, PhD; W. H. Wilson Tang, MD;
Stanley L. Hazen, MD, PhD
Background-—Trimethylamine-N-oxide (TMAO), a metabolite derived from gut microbes and dietary phosphatidylcholine, is linked
to both coronary artery disease pathogenesis and increased cardiovascular risks. The ability of plasma TMAO to predict 5-year
mortality risk in patients with stable coronary artery disease has not been reported. This study examined the clinical prognostic
value of TMAO in patients with stable coronary artery disease who met eligibility criteria for a patient cohort similar to that of the
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
Methods and Results-—We examined the relationship between fasting plasma TMAO and all-cause mortality over 5-year follow-up in
sequential patients with stable coronary artery disease (n=2235) who underwent elective coronary angiography. We identiﬁed the
COURAGE-like patient cohort as patients who had evidence of signiﬁcant coronary artery stenosis and who were managed with
optimal medical treatment. Higher plasma TMAO levels were associated with a 4-fold increased mortality risk. Following adjustments
for traditional risk factors, high-sensitivity C-reactive protein, and estimated glomerular ﬁltration rate, elevated TMAO levels remained
predictive of 5-year all-cause mortality risk (quartile 4 versus 1, adjusted hazard ratio 1.95, 95% CI 1.33–2.86; P=0.003). TMAO
remained predictive of incident mortality risk following cardiorenal and inﬂammatory biomarker adjustments to the model (adjusted
hazard ratio 1.71, 95% CI 1.11–2.61; P=0.0138) and provided signiﬁcant incremental prognostic value for all-cause mortality (net
reclassiﬁcation index 42.37%, P<0.001; improvement in area under receiver operator characteristic curve 70.6–73.76%, P<0.001).
Conclusions-—Elevated plasma TMAO levels portended higher long-term mortality risk among patients with stable coronary artery
disease managed with optimal medical treatment. ( J Am Heart Assoc. 2016;5:e002816 doi: 10.1161/JAHA.115.002816)
Key Words: optimal medical treatment • prognosis • stable coronary artery disease • trimethylamine N-oxide
T he prevalence of coronary artery disease (CAD) continuesto increase and remains the leading cause of death
worldwide.1 Despite advances in medical treatment, contem-
porary coronary revascularization techniques, and risk factor
modiﬁcation, the mortality risk of CAD remains high.1–3 There is
a pressing need to identify residual risk factors to improve our
understanding of the processes contributing to CAD and
vulnerable plaquepathogenesis and to identify novel therapeutic
targets in CAD. Recently, our group identiﬁed a novel mecha-
nistic link between trimethylamine-N-oxide (TMAO), an intestinal
microbiota-generated metabolite, and cardiovascular disease
(CVD) pathogenesis by a pathway involving dietary ingestion of
nutrients containing trimethylamine, including phosphatidyl-
choline, choline, and L-carnitine.4–10 These nutrients are more
abundant in a Western diet rich in red meat, egg yolk, and meat
products—a diet strongly associated with increased incident
CVD risks.5,11,12 Elevated plasma TMAO levels have shown
TMAO to be a proatherogenic biomarker and predictor of
adverse CVD risks in multiple cohorts.4,6–9,13–17
The Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) trial showed no
signiﬁcant difference in death and myocardial infarction risks
for stable CAD patients who were treated with
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revascularization plus optimal medical treatment (OMT)
versus OMT alone.18 We sought to examine the relationship
between fasting plasma TMAO levels and long-term clinical
prognosis in patients with stable CAD who had signiﬁcant
coronary artery stenosis detected on elective coronary
angiography and were managed with OMT alone (COURAGE-
like patient cohort).
Methods
Study Population
This single-center prospective cohort study was approved by
the Cleveland Clinic institutional review board. All participants
provided written informed consent. We included adult partic-
ipants (aged ≥18 years) with symptoms or signs of CAD who
underwent elective nonurgent coronary angiography at the
Cleveland Clinic between 2001 and 2007 without evidence of
acute coronary syndrome (cardiac troponin I <0.03 ng/mL).
Patients who had experienced acute coronary syndrome or
revascularization procedures within 30 days before enrollment
were excluded. A COURAGE-like patient cohort was identiﬁed
for the present studies by using COURAGE inclusion and
exclusion criteria,18 as follows: (1) patients who had an elective
diagnostic coronary angiography procedure, as described
earlier; (2) patients with evidence of signiﬁcant CAD deﬁned
by ≥70% diameter stenosis in at least 1 epicardial coronary
artery; and (3) patients assigned to receive OMT alone, without
a revascularization procedure within 30 days after enrollment
in the present study. All angiogram interpretations and the
decision of whether to undergo revascularization plus OMT or
OMT alone were determined at the discretion of the board-
certiﬁed cardiology staff at the Cleveland Clinic. A total of 2235
consecutive patients who fulﬁlled criteria for the COURAGE-like
patient cohort were included in this study and represent a
subset of the previously reported study cohort6 of medically
managed patients that fulﬁlled COURAGE trial criteria for having
signiﬁcant coronary artery disease. All-cause mortality at
5 years was tracked by electronic chart review and Social
Security Death Index up to 2011 and conﬁrmed by telephone
interviews, ofﬁcial hospital records, or death certiﬁcates.
Laboratory Testing
Fasting blood samples were collected using EDTA tubes at the
time of cardiac catheterization, immediately prior to heparin
injection and catheterization procedure. Samples were main-
tained on ice or at 4°C, immediately processed within 3 hours
of collection, and frozen at80°C until analysis. Routine
laboratory tests including high-sensitivity C-reactive protein
(hsCRP) and cardiac-speciﬁc troponin I were performed on
samples using the Abbott Architect platform (Abbott
Laboratories). An estimated glomerular ﬁltration rate (eGFR;
in mL/min per 1.73 m2) was calculated using the Modiﬁcation
of Diet in Renal Disease study equation.19Myeloperoxidasewas
measured using the CardioMPO assay (Cleveland HeartLab).
TMAO levels in plasma were determined using stable isotope
dilution high-performance liquid chromatography with online
electrospray ionization tandem mass spectrometry on an AB
Sciex API 5000mass spectrometer using d9-(trimethyl)-labeled
internal standards, as described previously.4,20
Statistical Analyses
Continuous data are presented as mean (standard deviation) or
median (interquartile range) and compared with Student t test
or nonparametric test when appropriate. Categorical variables
are presented as number (percentage) and compared between
groups with chi-square tests. We divided plasma TMAO levels
into quartiles. Kaplan–Meier analysis with Cox proportional
hazards regression was used for the time-to-event analysis to
determine hazard ratios (HRs) and 95% CIs for 5-year all-cause
mortality stratiﬁed according to TMAO quartiles. Adjustments
were made for individual traditional cardiovascular risk factors
(age, sex, systolic blood pressure, diabetes mellitus, low- and
high-density lipoprotein cholesterol levels, and smoking status),
number of diseased vessels, medications (angiotensin-convert-
ing enzyme inhibitor, angiotensin-receptor blocker, aspirin, or
statin), log-transformed hsCRP levels, eGFR, myeloperoxidase,
and B-type natriuretic peptide to predict all-cause mortality.
Category-free net reclassiﬁcation and area under the receiver
operating characteristic curve were calculated according to
mortality risk estimated using Cox models adjusted for the
above-mentioned traditional risk factors with versus without
TMAO, as described previously.21 All analyses were performed
used R 2.15.1 (R Foundation for Statistical Computing). P<0.05
indicated statistical signiﬁcance.
Results
Baseline Characteristics
The baseline characteristics of our study cohort are provided
in Table 1. The median TMAO level was 3.8 lmol/L (in-
terquartile range 2.5–6.5 lmol/L). Participants with higher
TMAO levels were more likely to be older, to have hyperten-
sion or diabetes, and to have lower eGFR.
Baseline Fasting Plasma TMAO and All-Cause
Mortality
Over 5 years of follow-up, 338 deaths occurred in our study
cohort. Figure 1 represents the Kaplan–Meier analysis of
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TMAO stratiﬁed by quartiles, which illustrate a graded
increased risk for all-cause mortality observed with increasing
plasma TMAO levels (log-rank, P<0.001). Importantly, the
highest TMAO quartile (>6.5 lmol/L) was associated with a
signiﬁcant 3.9-fold increased risk for all-cause mortality
compared with the lowest TMAO quartile (quartile 4 versus
1, unadjusted HR 3.90, 95% CI 2.78–5.48; P<0.0001)
(Table 2). The signiﬁcant prognostic value of elevated plasma
TMAO level was preserved when adjusted for traditional risk
factors (adjusted HR 2.61, 95% CI 1.82–3.76; P<0.0001),
with the addition of hsCRP and eGFR (adjusted HR 1.95, 95%
CI 1.33–2.86; P=0.003), and following the addition of B-type
natriuretic peptide, myeloperoxidase, number of diseased
vessels, and medications to the model (adjusted HR 1.71,
95% CI 1.11–2.61; P=0.0138) (Table 2). The addition of
TMAO to a model of traditional cardiovascular risk factors
showed that elevated TMAO level signiﬁcantly improved net
reclassiﬁcation for all-cause mortality (net reclassiﬁcation
index 42.37%; P<0.001) and area under the receiver
operating characteristic curve (70.6–73.76%; P<0.001). As
Table 1. Baseline Characteristics
Variable
All
(n=2235)
Trimethylamine-N-Oxide Quartiles
P Value
Quartile 1,
<2.5
Quartile 2,
2.5–3.8
Quartile 3,
3.81–6.5
Quartile 4,
>6.5
Age, y 6311 6011 6210 6510 6610 <0.001
Female, % 29 23 27 31 36 <0.001
Diabetes mellitus, % 35 27 31 34 49 <0.001
Hypertension, % 76 72 73 75 83 <0.001
Former/current smokers, % 70 73 71 68 67 0.106
History of coronary artery
disease, %
95 96 95 94 96 0.43
Framingham ATP III risk score 9 (6–12) 8 (5–10) 9 (6–11) 9 (7–12) 10 (7–13) <0.001
Low-density lipoprotein
cholesterol, mg/dL
92 (76–112) 93 (77–112) 95 (77–115) 92 (76–112) 89 (71–109) <0.001
High-density lipoprotein
cholesterol, mg/dL
33 (27–39) 33 (28–39) 33 (28–40) 34 (28–39) 31 (26–38) <0.001
Triglycerides, mg/dL 124 (89–180) 123 (90–175) 120 (88–167) 128 (90–182) 128 (89–195) <0.001
High-sensitivity C-reactive protein,
mg/L
2.6 (1.1–6.4) 2.6 (0.9–7.3) 2.4 (1.1–6.0) 2.5 (1.2–5.4) 3.1 (1.3–7.6) <0.001
Estimated glomerular filtration
rate, mL/min/1.73 m2
98.7 (74.4–125) 113.9 (92.5–135.2) 106.3 (83.5–131.2) 94.8 (72.5–119.6) 77.9 (52.9–104) <0.001
Apolipoprotein B, mg/dL 81 (68–96) 83 (69–97) 82 (69–98) 80 (68.2–94) 80 (67–93.2) <0.001
Apolipoprotein A1, mg/dL 113 (100–129) 112 (99–127) 114 (102–129) 115 (103–131) 112 (98–128) <0.001
Triglycerides/high-density
lipoprotein
3.9 (2.5–5.9) 3.7 (2.5–5.8) 3.7 (2.4–5.5) 3.9 (2.6–5.9) 4.2 (2.6–6.6) <0.001
Myeloperoxidase, pmol/L 112.5 (74.5–239.6) 125.1 (75.5–278.2) 113.5 (76.5–268.9) 112 (77.6–210.8) 104.5 (71.5–204.4) <0.001
White blood cell count,
per mm3
6.2 (5.1–7.6) 6.3 (5.3–7.9) 6.1 (5.1–7.5) 6.1 (5.1–7.5) 6.1 (5.1–7.4) <0.001
Medication
Angiotensin-converting
enzyme inhibitor
or angiotensin-receptor
blocker, %
55 50 52 57 59 0.004
Beta-blocker, % 70 71 69 72 69 0.702
Statin, % 71 75 70 70 67 0.029
Aspirin, % 81 83 83 81 76 0.008
Trimethylamine-N-oxide, lmol/L 3.8 (2.5–6.5) 1.8 (1.4–2.2) 3.1 (2.8–3.4) 4.9 (4.3–5.6) 9.7 (7.7–14.9) <0.001
Values expressed as meanSD, percentage or median (interquartile range).
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illustrated by the cubic spline curve, the risk of future
mortality appeared to be steep and linear, with HR signif-
icantly above unity, particularly for plasma TMAO levels
>4.5 lmol/L (Figure 2). Moreover, higher TMAO levels also
predicted higher future risk of 5-year all-cause mortality
regardless of age, sex, smoking status, diabetes mellitus,
and CVD risk markers including myeloperoxidase, lipids and
lipoproteins, hsCRP, eGFR, or B-type natriuretic peptide
(Figure 3).
Discussion
We observed that baseline fasting plasma TMAO levels
provided strong prognostic information about 5-year all-cause
mortality in stable CAD patients with signiﬁcant epicardial
coronary artery stenosis who were managed with OMT
(COURAGE-like patient cohort). The strong prognostic value
associated with elevated TMAO level was independent of
traditional risk factors, cardioprotective medication history
(angiotensin-converting enzyme inhibitor, angiotensin-receptor
blocker, aspirin, or statin), markers of systemic and vascular
inﬂammation (hsCRP, myeloperoxidase), and cardiorenal
indices (B-type natriuretic peptide and eGFR). The present
ﬁndings conﬁrm incremental prognostic value for TMAO in a
patient population with established atherosclerotic burden,
raising the possibility that interventions designed to target this
pathway may provide independent risk-reduction value.
Our recent studies demonstrated that TMAO is a
proatherogenic metabolite produced by gut microbes, and
increased levels of plasma TMAO are associated with CVD
risks and greater numbers of diseased major coronary vessels
observed by angiography.4 We also reported a strong
association between elevated plasma TMAO levels and
increased risk of adverse cardiovascular events in stable
patients undergoing elective diagnostic cardiac catheteriza-
tion, which included participants both with and without
angiographic evidence of CAD.6 In the present prospective
study, we identiﬁed stable CAD patients who fulﬁlled criteria
for the COURAGE trial-like patient cohort18 to evaluate the
clinical prognostic value of TMAO levels among participants
for whom OMT was selected and for whom no revasculariza-
tion events occurred within 30 days of the index coronary
angiographic study. In addition to COURAGE, other trials
involving patients with stable CAD have supported initial
medical treatment as an appropriate ﬁrst approach2,18,22;
Figure 1. Unadjusted Kaplan–Meier estimates of risk of all-
cause mortality according to the quartiles of plasma TMAO levels.
TMAO indicates trimethylamine-N-oxide.
Table 2. Cox Proportional Hazards Analyses of Fasting
Plasma Trimethylamine-N-Oxide Levels for 5-Year All-Cause
Mortality
Model Hazard Ratio (95% CI) P Value
Unadjusted 3.90 (2.78–5.48) <0.0001
Adjusted Model 1 2.61 (1.82–3.76) <0.0001
Adjusted Model 2 1.95 (1.33–2.86) 0.003
Adjusted Model 3 1.71 (1.11–2.61) 0.0138
Hazard ratios shown are for quartile 4 vs 1. Model 1: adjusted for traditional risk factors
including age, sex, systolic blood pressure, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, smoking, and diabetes mellitus. Model 2: adjusted for all
factors in model 1 plus high-sensitivity C-reactive protein (log-transformed) and
estimated glomerular ﬁltration rate. Model 3: adjusted for all factors in model 1 plus
medications (angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, b-
blocker, aspirin, or statin), number of stenotic vessels, high-sensitivity C-reactive protein
(log-transformed), myeloperoxidase (log-transformed), estimated glomerular ﬁltration
rate (log-transformed), and B-type natriuretic peptide (log-transformed).
Figure 2. Cubic spline curve for hazard ratios for all-cause
mortality at 5 years with plasma TMAO levels. TMAO indicates
trimethylamine-N-oxide.
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however, all of those studies revealed signiﬁcant residual
cardiovascular risks, and methods to both identify those at
increased risk despite optimal medical therapy and potential
novel therapeutic targets are needed. In the present study, we
included only participants with signiﬁcant stenosis of ≥70% ≥1
epicardial coronary artery, similar to inclusion criterion used
in the COURAGE trial18 and widely accepted for anatomically
signiﬁcant stenosis assessed by angiogram.2 Despite
adjustments for known CVD risk factors, medications, and
markers of both inﬂammation and cardiorenal indices, TMAO
levels were found to provide signiﬁcant additive prognostic
value. Moreover, addition of TMAO to traditional risk factors
and laboratory tests resulted in signiﬁcant net reclassiﬁcation
of participants (42.4%; P<0.001). Our present study showed,
for the ﬁrst time, that plasma TMAO levels are a powerful
prognostic marker among patients with stable CAD who opt
for medical therapy (ie, in a COURAGE-like patient cohort).
This study suggests that use of TMAO among stable CAD
patients should help identify those with signiﬁcant residual
CVD risks. Because TMAO itself is proatherogenic, one can
speculate that the present study also suggests that elevated
TMAO levels may help identify patients for whom a TMAO-
lowering intervention (eg, dietary, drug, probiotic) may provide
beneﬁt. In addition, the present study suggests that use of
TMAO as a screening criterion for enrollment into future CVD
outcome trials among stable CAD patients may help enrich
the study to contain participants at increased incident
mortality risk.
TMAO has been shown previously to directly promote
proatherosclerotic effects and to have a direct mechanistic
link to adverse cardiovascular outcomes in both animal
models and human studies.4,6–9,13–17,23 TMAO is cleared by
the kidney, and a higher plasma TMAO level was associated
with worse long-term survival in patients with chronic kidney
disease8,15,16 and with heart failure.7,10,17,24 Interestingly, the
association between TMAO and long-term mortality in the
present study cohort remained robust after adjustment for
eGFR or cardiorenal indices, although the kidneys may be
physiologically impaired in eliminating TMAO. The precise
mechanisms through which TMAO is linked to enhanced
cardiovascular disease risks are unclear; however, prior
mechanistic studies provide some potential insights. Provision
of TMAO, for example, in the diet or enhanced production via
dietary intake of nutritional precursors including choline and
carnitine has been shown to both enhance aortic root
atherosclerotic plaque development and to inhibit reverse
cholesterol transport.4,5 TMAO also signiﬁcantly affected
macrophage phenotype, bile acid synthesis, pool size and
composition, and multiple bile and sterol transporters in both
the liver and the intestines.4,5 The metaorganismal pathway
responsible for TMAO production has similarly been linked
mechanistically to multiple cardiovascular and metabolic
processes associated with CVD pathogenesis. Several recent
studies suggest, for example, that ﬂavin-containing monooxy-
genase 3, the host enzyme primarily responsible for convert-
ing intestinal microbiota-generated trimethylamine into
TMAO, is an important regulator of body cholesterol and
sterol metabolism as well as additional lipid and metabolic
pathways.25–28 In addition, knockdown of hepatic ﬂavin-
containing monooxygenase 3 in low-density lipoprotein
Figure 3. Relationship between plasma TMAO concentration
and mortality risk stratiﬁed according to clinical and laboratory
subgroups. Forest plot of hazard ratio (squares) of 5-year all-
cause mortality comparing fourth and ﬁrst quartiles of plasma
TMAO levels. Bars represent 95% CIs. ApoA1 indicates
apolipoprotein A1; ApoB, apolipoprotein B; BNP, B-type natriuretic
peptide; eGFR, estimated glomerular ﬁltration rate; hsCRP, high-
sensitivity C-reactive protein; LDL, low-density lipoprotein; MPO,
myeloperoxidase; TMAO indicates trimethylamine-N-oxide.
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receptor knockout mice using an antisense oligonucleotide
resulted in decreased circulating TMAO levels and atheroscle-
rosis, providing further mechanistic support of the importance
of the TMAO pathway to vascular disease pathogenesis in
animal models.25 TMAO may also exacerbate impaired
glucose tolerance and promote adipose tissue inﬂammation,
which are related to the complexity and degree of atheroscle-
rosis burden of CAD.25,29 Recently, exciting new animal data
also suggested that targeting gut microbial TMAO production
can inhibit dietary-induced atherosclerosis.30 Furthermore, a
role for gut microbiota and TMAO in modulating platelet
hyperresponsiveness and thrombosis potential was discov-
ered recently.31
Many factors may inﬂuence circulating TMAO levels, and
there have also been reports with discrepant ﬁndings. Mueller
and colleagues, for example, observed in a cohort of 339
patients undergoing angiographic evaluation that TMAO levels
were confounded by impaired kidney function and poor
metabolic control and were not associated with history,
presence, or incidence of symptoms or events of CAD.32
Interestingly, levels reported in the study by Mueller et al
were markedly lower than those described in our current
study (median TMAO 1.74 lmol/L; third-quartile TMAO 3.48
lmol/L). Furthermore, some of the most accepted cardio-
vascular risk biomarkers such as low-density lipoprotein
cholesterol, triglyceride, and glucose and hsCRP can be highly
variable, more so even than TMAO. Further study is needed to
determine whether interventions that reduced TMAO levels
also improved prognosis among patients with high atheroscle-
rotic burden.
Study Limitations
This single tertiary care center study recruited patients at the
time of cardiac evaluation for coronary angiography; therefore,
we cannot exclude the presence of selection bias for patients
undergoing evaluation and treatment for CAD. Because plasma
TMAO levels were measured at only 1 point in time, we were
unable to evaluate the prognostic value of changing plasma
TMAO concentration over time. Similarly, only fasting plasma
levels were examined, and it remains unknown if nonfasting
TMAO levels provide similar prognostic value.
Conclusions
Among participants with angiographic evidence of signiﬁcant
(≥70% stenosis) CAD and for whom medical management was
chosen, elevated plasma TMAO levels portended higher long-
term mortality risk independent of traditional risk factors,
inﬂammation markers, B-type natriuretic peptide levels, and
renal function.
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